BCL2 and cancer: Additionally, galangin mitigates cisplatin resistance in lung cancer (A549) cells by suppressing the p-STAT3/p65 and Bcl-2 signaling pathways, further demonstrating its potential as therapeutic agent in resistant cancer (13, 71).